Background: The pathogenesis of macrophage activation syndrome (MAS) is not clearly understood: a large body of evidence supports the involvement of mechanisms similar to those implicated in the setting of primary hemophagocytic lymphohistiocytosis. Objective: We sought to investigate the pathogenic role of IFN-g and the therapeutic efficacy of IFN-g neutralization in an animal model of MAS. Methods: We used an MAS model established in mice transgenic for human IL-6 (IL-6TG mice) challenged with LPS (MAS mice). Levels of IFN-g and IFN-g-inducible chemokines were evaluated by using real-time PCR in the liver and spleen and by means of ELISA in plasma. IFN-g neutralization was achieved by using the anti-IFN-g antibody XMG1.2 in vivo. Results: Mice with MAS showed a significant upregulation of the IFN-g pathway, as demonstrated by increased mRNA levels of Ifng and higher levels of phospho-signal transducer and activator of transcription 1 in the liver and spleen and increased expression of the IFN-g-inducible chemokines Cxcl9 and Cxcl10 in the liver and spleen, as well as in plasma. A marked increase in Il12a and Il12b expression was also found in livers and spleens of mice with MAS. In addition, mice with MAS had a significant increase in numbers of liver CD68 1 macrophages. Mice with MAS treated with an anti-IFN-g antibody showed a significant improvement in survival and body weight recovery associated with a significant amelioration of ferritin, fibrinogen,
Macrophage activation syndrome (MAS) is a term used to identify hemophagocytic lymphohistiocytosis (HLH) secondary to rheumatic diseases. 1, 2 It is a severe and potentially fatal condition that occurs in the context of rheumatic diseases, particularly systemic juvenile idiopathic arthritis (sJIA). 3 MAS is classified among the secondary HLHs and shares clinical and biochemical features with familial or primary hemophagocytic lymphohistiocytosis (pHLH). 4 A cytokine storm appears to be the driving feature 5 ; the ensuing clinical syndrome is characterized by high fever, pancytopenia, hyperferritinemia, hypofibrinogenemia, hepatosplenomegaly, and intravascular coagulation. 6 The triggering mechanism behind pHLH is a defect in cytotoxicity caused by mutations in genes encoding proteins required for cytotoxic activity of lymphocytes and natural killer cells. 7 The pathogenesis of MAS is not clearly understood. 8 A large body of evidence supports the involvement of mechanisms similar to those implicated in patients with pHLH. Indeed, patients with JIA with MAS have been shown to have transient natural killer cell dysfunction, such as decreased cell numbers and activity, and reduced perforin expression. [9] [10] [11] Recently, in patients with sJIA and MAS, genetic studies, including whole-exome sequencing, identified rare proteinaltering variants in known pHLH-associated genes and new candidate genes that are possibly involved in intracellular granule trafficking, further suggesting that MAS predisposition in patients with sJIA could be attributed, at least in part, to variants of genes involved in the cytolytic pathways. [12] [13] [14] Consistent with these data, Sepulveda et al 15 demonstrated that the accumulation of monoallelic mutations in HLH-causing genes increases susceptibility to HLH immunopathology also in mice.
Studies in patients and in animal models of pHLH have suggested a key role of IFN-g in the pathogenesis of the disease. Indeed, in a large cohort of children with HLH, highly increased levels of IFN-g correlated with disease activity have been reported. 16 Moreover, in perforin 2/2 mice infected with lymphocytic choriomeningitis virus, the high amount of IFN-g produced by CD8 1 T cells has been demonstrated to be uniquely essential for disease development. 17 Similarly, in lymphocytic choriomeningitis virus/Rab27a-deficient mice, neutralization of IFN-g has been shown to revert central nervous system involvement and reduce hemophagocytosis. 18 Neutralization of IFN-g is able to revert hematologic abnormalities also in the mouse model of HLH secondary to infections, which was mimicked by repeated stimulation of Toll-like receptor (TLR) 9 on a normal genetic background. 19 The aim of this study was to evaluate the pathogenic role of IFN-g in a mouse model of MAS based on mice transgenic for human IL-6 (IL-6TG mice). 20 We have reported that IL-6TG mice, after a single administration of TLR ligands, display an increased fatality rate associated with higher levels of circulating proinflammatory cytokines and hematologic and biochemical features typically present in mice with MAS. 20 In these mice MAS is induced by mimicking an acute infection with administration of a TLR agonist (ie, LPS). This approach recapitulates what occurs in patients with sJIA: an infection is the typical trigger of MAS in the presence of active disease, which is characterized by high levels of IL-6, which appears to play a pivotal pathogenic role in the autoinflammation of sJIA. 21, 22 In this study we investigated whether levels of IFN-g and IFN-g-inducible chemokines are increased in the setting of MAS induced by LPS in IL-6TG mice and whether administration of an anti-IFN-g antibody improves survival and disease parameters.
METHODS

Mice and in vivo treatments
The IL-6TG mouse has been described previously. 23 Mice between 10 and 14 weeks of age were administered intraperitoneally a single dose (7.5 or 5 mg/g body weight) of LPS (Escherichia coli serotype 055:B5; Sigma-Aldrich, St Louis, Mo). For treatment experiments, 100 mg/g body weight of the anti-mouse IFN-g neutralizing antibody XMG1.2 (BioXCell, West Lebanon, NH) and of a rat IgG 1 isotype-matched control mAb35 (American Type Culture Collection, Manassas, Va) were administered to mice intraperitoneally. Mice were maintained under specific pathogen-free conditions and handled in accordance with the institutional experimental ethics committee guidelines.
Cytokine, ferritin, fibrinogen, and alanine aminotransferase measurements
Mouse plasma cytokine and chemokine levels were determined by using MILLIPLEX MAP Multiplex Immunodetection Kits (Merck, Whitehouse Station, NJ), according to the manufacturer's instructions. For all analytes, the lower detection limit was 3.2 pg/mL, and the upper detection limit was 10,000 pg/mL. CXCL9 and CXCL10 levels were further determined by using mouse Quantikine ELISA KITs (R&D Systems, Minneapolis, Minn). Serum ferritin and plasma fibrinogen concentrations were determined by using ELISA kits (ALPCO Diagnostics, Salem, NH, and Abcam, Cambridge, United Kingdom, respectively). Alanine aminotransferase (ALT) levels were determined by using an enzymatic assay kit (Bioo Scientific, Austin, Tex).
RNA isolation and quantitative real-time PCR
Total RNA was extracted from mouse liver and spleen tissues with TRIzol (Life Technologies, Grand Island, NY), and cDNA was obtained with the Superscript Vilo Kit (Invitrogen, Carlsbad, Calif). Real-time PCR assays were performed with the TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, Calif) and the following gene expression assays: mouse Ifng, Cxcl9, Cxcl10, Il12a, and Il12b (Applied Biosystems). Gene expression data were normalized with mouse Hprt (Applied Biosystems) as an endogenous control. Data are expressed as arbitrary units determined by using the 2 2Dct method.
Protein extraction and Western blot analysis
Total tissue proteins were extracted with RIPA Buffer (Cell Signaling, Danvers, Mass). For Western blotting, protein lysates were resolved by using 10% SDS-PAGE. Proteins were then transferred to nitrocellulose membranes (Amersham Life Sciences, Piscataway, NJ) and probed with antibodies to phospho-Tyr701 signal transducer and activator of transcription (STAT) 1, total STAT1, and glyceraldehyde-3-phosphate dehydrogenase (all from Cell Signaling) by using standard procedures.
Histology and immunohistochemical analysis
Livers from mice were drop fixed in neutral buffered formalin and then processed for paraffin embedding. Sections of 2.5 mm were stained with hematoxylin and eosin. For immunohistochemical analysis, after moist heat-induced antigen retrieval with EnVision Flex Target Retrieval Solutions High pH (DakoCytomation, Glostrup, Denmark), 2.5-mm sections were incubated with antibody to CD68 (Abcam, Cambridge, United Kingdom) overnight at 48C. After washing, sections were incubated with appropriate horseradish peroxidase-conjugated secondary antibodies. Chromogen detection was carried out with the DAB chromogen kit (DakoCytomation). Nuclei were counterstained with hematoxylin, followed by dehydration and mounting. The number of CD68 1 cells was enumerated in at least 10 fields for each tissue at 340 magnification.
Statistical analyses
Data are presented as means 6 SEMs, unless otherwise indicated. Group comparisons were performed with the nonparametric Mann-Whitney U test. The Spearman rank correlation coefficient (r) was calculated to assess correlations between variables. All statistical analyses were performed with GraphPad Prism IV software (GraphPad Software, La Jolla, Calif). A P value of less than .05 was considered statistically significant.
RESULTS
IFN-g and IFN-g-inducible chemokine levels are higher in LPS-challenged IL-6TG mice Although Ifng mRNA expression levels were not different between wild-type (WT) and IL-6TG mice in both the liver (Fig 1, A) and spleen (Fig 1, C) before LPS administration, we found that they were significantly increased in IL-6TG mice compared with WT mice at 12 hours after LPS administration (Fig 1, A and C) . Moreover, we found that Cxcl9 mRNA levels were significantly higher in the liver and Cxcl10 mRNA levels were significantly higher both in the liver and spleen compared with those in WT mice (Fig 1, A and C) .
Liver and spleen protein lysates were tested by using Western blotting with a specific antibody for Tyr701-phosphorylated STAT1, which is known to mediate IFN-g effects, to further evaluate activation of the IFN-g pathway in LPS-challenged IL-6TG mice compared with WT mice. 24, 25 We did not detect Tyr701 phosphorylation of STAT1 before LPS challenge in both WT and IL-6TG mouse tissues. Tyr701-phosphorylated STAT1 was similarly increased both in the liver (Fig 1, B) and spleen (Fig 1, D) in WT and IL-6TG mice at 6 hours after LPS challenge.
Notably, although in WT mice phospho-STAT1 levels returned to baseline at 12 hours after LPS challenge, in IL-6TG mice they remained markedly higher both in the liver and spleen (Fig 1, B and D).
Because IL-12, which is produced mainly by classically activated M1 macrophages, 26 is known to stimulate IFN-g
LPS-challenged IL-6TG mice display upregulation of the IFN-g pathway and increased mRNA expression of Il12a and Il12b. WT and IL-6TG mice were challenged with LPS (5 mg/g body weight), and at different times after the challenge, mice were killed. A and C, mRNA expression levels of Ifng and of the IFN-g-regulated genes Cxcl9 and Cxcl10 were assayed in the liver (Fig 1, A) and spleen (Fig 1, C) . Results are expressed as arbitrary units (AU) and obtained after normalization with the housekeeping gene Hprt. Tyr701-phosphorylated STAT1 protein levels were assessed by means of Western blot analysis in the liver (B) and spleen (D). In Fig 1, B and D, at right, densitometric analyses confirmed the increased levels of Tyr701-phosphorylated STAT1 in the liver and spleen from IL-6TG mice compared with WT mice (n 5 4 or 5 in each group). E and F, mRNA expression levels of Il12a and Il12b were also evaluated in the liver (Fig 1, E) and spleen (Fig 1, F) . Data in Fig 1, A-F (means 6 SEMs), are representative of at least 2 independent experiments with at least 3 mice in each group. Statistical analyses were performed with the 1-tailed Mann-Whitney U test: *P < .05, **P < .01, and ***P < .001.
Circulating levels of IFN-g-inducible chemokines and proinflammatory cytokines are increased in LPS-challenged IL-6TG mice. Plasma levels of IFN-g, the IFN-g-inducible chemokines CXCL9 and CXCL10, and the proinflammatory cytokines IL-1b, IL-6, and TNF-a were measured in WT and IL-6TG mice at 18 hours after challenge with LPS (5 mg/g body weight). Data (means 6 SEMs) are representative of at least 2 independent experiments with at least 3 mice in each group. Statistical analyses were performed with the 1-tailed Mann-Whitney U test: *P < .05, **P < .01, and ***P < .001.
production and has been demonstrated to act upstream to induce IFN-g in an animal model of fulminant MAS, 27 we assessed mRNA expression of the Il12a and Il12b genes, encoding for the 2 heterologous chains of IL-12 p35 and p40, respectively. We found that these genes were strongly upregulated in livers from LPS-challenged IL-6TG mice and significantly higher in both the liver and spleen in IL-6TG mice compared with WT mice (Fig 1, E and F) . In IL-6TG mouse livers, strong positive correlations between Il12a and Il12b and Ifng mRNA expression were also found (r 5 0.93, P 5 .001 and r 5 0.083, P 5 .007, respectively), further suggesting a possible role for IL-12 in inducing IFN-g production in the tissue.
When we measured circulating levels of IFN-g, low levels (in the picogram per milliliter range) were detected, with a trend for higher levels in LPS-challenged IL-6TG mice compared with WT mice (Fig 2) . These results are consistent with recent observations demonstrating that production of IFN-g typically occurs in peripheral tissues. 28 In this respect circulating levels of the IFN-g-inducible chemokines CXCL9 and CXCL10 have been suggested as possible markers of tissue IFN-g production. Indeed in LPS-challenged IL-6TG mice, high levels of CXCL9 and CXCL10 were found in plasma (Fig 2) .
Interestingly, we found also that circulating levels of CXCL9 were significantly correlated with liver mRNA levels (18 hours after LPS administration) of Ifng (r 5 0.83, P 5 .029) and Cxcl9 (r 5 0.89, P 5 .017). Similarly, circulating CXCL10 levels were significantly correlated to liver mRNA levels of Ifng (r 5 0.82, P 5 .030) and Cxcl10 (r 5 0.89, P 5 .017). We also found a tight correlation between plasma CXCL9 levels and spleen Cxcl9 mRNA levels (r 5 1.0, P 5 .001). The same analyses were performed in WT mice, and no correlations were observed. Furthermore, and consistent with previously published data at 6 hours from LPS challenge, 20 at 18 hours, levels of proinflammatory cytokines, including IL-1b, TNF-a, and IL-6, were markedly higher in LPS-challenged IL-6TG mice compared with WT mice (Fig 2) .
Altogether, our data show that in the mouse model of MAS, Ifng expression is increased, the STAT1-mediated IFN-g pathway is upregulated, and the IFN-g-inducible chemokines are upregulated locally and systemically. The significant correlation between Ifng and chemokine transcript levels in peripheral tissues and chemokine levels in the blood supports the conclusion that circulating levels of IFN-g-inducible chemokines reflect tissue activation of the IFN-g pathway, as well as tissue production of IFN-g-inducible chemokines.
Incidentally, liver hematoxylin and eosin staining did not reveal major abnormalities in hepatocytes. However, dilated sinusoids populated by mononucleated cells were observed in LPS-challenged IL-6TG mice but not in WT mice (Fig 3, A) . (Fig 3, B) , suggesting a role for macrophages in the development of the disease in IL-6TG mice.
Neutralization of IFN-g improves survival, body weight recovery, and laboratory parameters in LPS-challenged IL-6TG mice
Having demonstrated that the IFN-g pathway is upregulated in murine MAS induced by LPS challenge in IL-6TG animals, the effect of neutralization of IFN-g was tested by administering an anti-IFN-g antibody. After control antibody administration, all mice challenged with a dose of LPS known to be lethal in 100% of the animals (7.5 mg/g body weight) died within 4 days, whereas 70% of mice treated with the anti-IFN-g antibody survived (Fig 4, A) . Similarly, after control antibody administration, 5 of 10 mice challenged with a dose of LPS known to be lethal in 50% of animals (5 mg/g body weight) died within 4 days, whereas all mice treated with the anti-IFN-g antibody survived (Fig 4, B) .
No additional deaths occurred in the following days in both groups of mice and in both experiments (data not shown).
In mice injected with 5 mg/g LPS, anti-IFN-g treatment significantly improved body weight recovery, with animals reaching their baseline weight within 3 days (Fig 4, C) . After 12 hours from LPS administration, a marked increase in ferritin levels was observed, which is consistent with previous data. 20 Although ferritin levels did not change in control antibody-treated IL-6TG mice, a sharp decrease was observed in mice treated with the anti-IFN-g antibody (Fig 4, D) . After LPS administration, levels of plasma fibrinogen, an additional laboratory feature of MAS, were significantly lower in IL-6TG mice compared with those in WT mice (mean 6 SD, 4229 6 1885 vs 6654 6 1526 mg/mL, P 5 .01), suggesting increased intravascular coagulation activation in this animal model. We found that in LPS-challenged IL-6TG mice fibrinogen levels were significantly higher in mice treated with the anti-IFN-g antibody compared with mice treated with the control antibody (Fig 4, E) .
To biochemically evaluate liver involvement, we measured ALT levels. As previously demonstrated, we did not observe a significant difference in circulating ALT levels between LPSchallenged IL-6TG and WT mice both at baseline and 12 hours after LPS (mean 6 SD: basal levels, 13.58 6 6.8 vs 12.2 6 10.07 U/L; 12 hours after LPS administration, 40.2 6 21.24 vs 38.7 6 15.30 U/L). In IL-6TG mice after administration of the anti-IFN-g antibody, ALT levels were significantly reduced compared with those in control-treated animals (Fig 4, F) .
IFN-g-inducible chemokines and proinflammatory cytokines are downregulated in mice treated with the anti-IFN-g antibody and are related to changes in ferritin levels during effective treatment
In anti-IFN-g antibody-treated IL-6TG mice plasma levels of CXCL9 and CXCL10 were markedly lower than those of mice treated with control antibody (Fig 5, A) . Moreover, plasma levels of IL-1b, IL-6, and TNF-a, 3 classical proinflammatory cytokines, were significantly lower in anti-IFN-g antibodytreated than in control antibody-treated mice (Fig 5, B) . Finally, in LPS-challenged mice treated with the control and the anti-IFN-g antibody, lower circulating levels of CXCL9 and CXCL10 were significantly associated with lower levels of IL-6, IL-1b, and TNF-a (Fig 6, A) , as well as with lower serum ferritin levels (Fig 6, B and C) . These results support the conclusion that a decrease in IFN-g activity, as estimated by the decrease in CXCL9 and CXCL10 levels, is related to downstream events, such as inflammatory cytokine levels and clinical parameters of disease. , and 12 hours after the challenge, mice were treated with the IFN-g neutralizing antibody XMG2.1 (100 mg/g body weight) or with the mAb35 control antibody. Eighteen hours after treatment with antibodies, mice were killed, and levels of CXCL9 and CXCL10 (A) and proinflammatory cytokines (B), including IL-1b, IL-6, and TNF-a, were assayed in plasma samples collected at the time of death. Data (means 6 SEMs) are representative of at least 2 independent experiments with at least 3 mice in each group. Statistical analyses were performed with the 1-tailed Mann-Whitney U test: *P < .05 and **P < .01.
FIG 4.
Treatment with a neutralizing anti-IFN-g antibody (Ab) improves survival and clinical and laboratory parameters of MAS in LPS-challenged IL-6TG mice. IL-6TG mice were challenged with 7.5 mg/g body weight of LPS (A) or with 5 mg/g body weight of LPS (B) at day 0, and 12 hours after the challenge, mice were treated with the IFN-g neutralizing antibody XMG2.1 (100 mg/g body weight) or with the control antibody mAb35 and were monitored for survival. Survival rates were determined every day for 4 days (n 5 10 mice per group). The Fisher exact test was performed. C-F, IL-6TG mice were challenged with LPS (5 mg/g body weight) at day 0 and treated, as previously described, with the XMG2.1 or mAb35 control antibody, and clinical and laboratory parameters were evaluated: body weight variation (Fig 4, C) and serum ferritin (Fig 4, D) , plasma fibrinogen (Fig 4, E) , and plasma ALT (Fig 4, F) levels. In Fig 4, A, average body weight loss data are presented with last observation carried forward for mice that succumbed to LPS challenge. Data (means 6 SEMs) are representative of at least 2 independent experiments with at least 3 mice in each group. Statistical analyses were performed with the 1-tailed Mann-Whitney U test: *P < .05 and **P < .01. 
DISCUSSION
Although several observations in murine models and indirect evidence in patients point to a pivotal pathogenic role of IFN-g in patients with pHLH, 17, 18 limited data are available on its role in pathogenesis of the different forms of secondary HLH. In this study we used a murine model of MAS in which clinical and laboratory features of MAS are induced by administration of a TLR ligand in IL-6 transgenic mice. 20 We found that IL-6TG mice challenged with LPS display upregulation of the IFN-g pathway, as shown by higher mRNA expression levels of Ifng, higher levels of phospho-STAT1 and the IFN-g-inducible genes Cxcl9 and Cxcl10 in the liver and spleen, and higher levels of circulating CXCL9 and CXCL10. Moreover, we found that treatment of IL-6TG mice with an anti-IFN-g antibody improved survival, body weight, and laboratory parameters. Finally, neutralization of IFN-g led also to a marked decrease in circulating levels of CXCL9 and CXCL10, chemokines typically induced by IFN-g, as well as of the downstream inflammatory cytokines TNF-a, IL-6, and IL-1b.
Despite the evidence that in normal mice systemic overexposure to high levels of IFN-g is sufficient to drive cytopenias and hemophagocytosis in a STAT1-dependent manner, 29 data on the role of IFN-g in models of secondary HLH are scarce and in part contradictory. In a model of HLH secondary to infections induced by TLR9-repeated stimulation, on a normal genetic background and in the absence of underlying disease, an important pathogenic role for IFN-g has been reported. 19 Moreover, by using IFN-g-overexpressing mice, IFN-g has been identified as a mediator of systemic inflammatory disease, supporting the hypothesis that there is a critical threshold of IFN-g that, when achieved either locally in tissues or systemically, drives the development of an autoinflammatorylike disease, interestingly with high ferritin levels. 30 In apparent contrast, immune stimulation of IFN-g knockout mice with Freund complete adjuvant produces a systemic inflammatory disease that includes features of sJIA, as well as MAS, such as anemia, increased numbers of immature blood cells, increased serum levels of IL-6, hemophagocytosis, and defective natural killer cell cytotoxicity; it is noteworthy that cytopenias and hyperferritenemia were not demonstrated in this model. 31 Canna et al 27 , and 12 hours after the challenge, mice were treated with the IFN-g neutralizing antibody XMG2.1 (100 mg/g body weight; solid squares) or with the mAb35 control antibody (open squares). Eighteen hours after treatment with antibodies, mice were killed, and levels of CXCL9 and CXCL10 were measured in plasma and related to circulating levels of the proinflammatory cytokines IL-6, IL-1b, and TNF-a (A), as well as to serum ferritin levels (B and C). The Spearman rank correlation coefficient was calculated (r) to assess correlations between variables.
hemophagocytosis arise. When these mice were knocked out for IFN-g, they had immunopathology and hemophagocytosis comparable with that seen in WT mice but did not become anemic and had greater numbers of splenic erythroid precursors. 27 Similarly, in a mouse model of HLH associated with cytomegalovirus-related sepsis, IFN-g knockout mice display a more severe spectrum of the disease, 32 therefore suggesting a protective role for IFN-g. The interpretation of these results, which appear to be at least in part contradictory, might be particularly difficult because of compensatory mechanisms secondary to a lack of or increased expression of IFN-g since prenatal age in these animal models.
Although these approaches provide a wealth of information on the pathophysiology of hyperinflammation, these compensatory mechanisms make it difficult to directly extrapolate the findings into a therapeutic approach in subjects with a ''normal'' immune response. Indeed, recently, 2 unrelated patients with novel mutations in IFN-g receptors, which is highly suggestive of functional receptor deficiency, have been described with a clinical presentation that closely resembled that of HLH in the context of overwhelming mycobacterial infections (with associated herpes virus infections). 33 This observation has suggested that IFN-g-independent pathways can contribute to the development of the clinical syndrome HLH or at least to some of the characteristic features.
As previously mentioned, animal models of pHLH caused by deletion of the genes involved in pHLH on an otherwise normal immune response have unequivocally demonstrated a pivotal pathogenic role of IFN-g. We have used a model in which MAS clinical and laboratory features are triggered in animals with high levels of circulating human IL-6 since early phases of life (not prenatally), with a normally regulated expression of IFN-g. 20 Our model has similarities with MAS development in patients with sJIA, where MAS is typically triggered by acute infections during an underlying case of active sJIA, which is typically characterized by increased IL-6 levels.
Our data show high mRNA expression of IFN-g associated with high Il12a and Il12b mRNA expression in the liver and spleen, suggesting that IL-12 might be at least one of the factors involved in increased production of IFN-g in the presence of high in vivo levels of IL-6. Overexpression of IFN-g is biologically relevant, as shown by the prolonged phosphorylation of STAT1 in the liver and spleen and by the marked upregulation of liver and spleen expression and plasma levels of IFN-g-inducible chemokines. These observations in the liver and spleen, which are target tissues in the setting of MAS, appear to complement observations in patients with secondary HLH 34 and MAS. Billiau et al 35 showed the presence of IFN-g-producing activated CD8 1 lymphocytes in 4 liver biopsy specimens of patients with secondary HLH, including 1 patient with MAS. More recently, high levels of IFN-g and CXCL10 in the sera of 5 patients with HLH, 3 of them with MAS, have also been reported. 36 Recently, we found high circulating levels of IFN-g and IFN-g-inducible chemokines in 20 patients with active MAS but not in patients with active sJIA without MAS. 37 It should be noted that gene expression profile studies of PBMCs of patients with active sJIA with or without MAS did not show an IFN-g signature. [38] [39] [40] However, although gene expression profile studies on PBMCs reveal events that occur in peripheral blood, our animal data in the liver and spleen support the hypothesis that, in patients with MAS, marked production of IFN-g and IFN-g-inducible proteins occurs first in diseased tissues, after which proteins leak into peripheral blood. Supporting this hypothesis, we found that in LPS-challenged IL-6TG mice there was a significant correlation of circulating levels of CXCL9 and CXCL10 with liver/spleen mRNA levels of Cxcl9 and Cxcl10 and, more importantly, with tissue mRNA levels of Ifng. Notably, Put et al 36 reported evident expression of the IFN-g-inducible proteins indoleamine 2,3-dioxygenase and CXCL10 in 1 lymph node biopsy specimen from 1 patient with sJIA with MAS. Furthermore, some of us demonstrated in the model of HLH secondary to infection induced by repeated TLR9 stimulation that total IFN-g levels produced in tissues are 500-to 2000-fold higher than those measured in blood and identified the spleen and liver as major sites of IFN-g production. 28 These results are consistent with our finding of a trend for increased circulating levels of IFN-g in our mice with MAS. Together, these observations in patients with MAS and in MAS animal models support the hypothesis that IFN-g production is markedly increased, that high IFN-g production is biologically relevant, and that overactivation of the IFN-g pathway appears to occur in peripheral tissues, which are typically involved by the disease, such as the liver and spleen.
We also demonstrated the pathogenic role of IFN-g in the murine MAS model. Treatment with an anti-IFN-g antibody led to a significant increase in survival and reverted clinical and laboratory features of MAS, including body weight loss and ferritin, ALT, and fibrinogen levels. Furthermore, neutralization of IFN-g led to a significant decrease in levels of classical downstream proinflammatory cytokines. Interestingly, we found that in LPS-challenged mice circulating CXCL9 and CXCL10 levels were significantly related to IL-1b, IL-6, TNF-a, and ferritin levels. Further supporting the relevance of IFN-g neutralization, we showed that the extent of change in upstream events (ie, CXCL9 and CXCL10 levels) is related to the extent of the decrease in downstream events, such as levels of proinflammatory cytokines, or even more so, levels of ferritin, a classical laboratory parameter of disease activity in clinical practice. Consistent with these data in mice, we found that in patients with MAS sampled longitudinally during effective traditional treatment, circulating levels of both CXCL9 and CXCL10 paralleled the decrease in ferritin levels during the progressive clinical improvement (data not shown). Data in animals and human subjects suggest also that serum levels of CXCL9 and possibly CXCL10, because they reflect tissue production of IFN-g, might represent additional biomarkers of disease activity in the setting of MAS. Their relative value compared with standard biochemical parameters, such as ferritin levels, in identifying patients in the early stages of MAS before it progresses to its life-threatening stage should be investigated in a larger number of patients, possibly in a multicenter study.
Our experimental model of MAS has the limitation of having short duration (death occurs in 2-4 days after LPS administration), therefore representing an acute model of the disease useful to study early stages (ie, induction mechanisms) of the disease. In contrast, we cannot evaluate improvement in late events, such as tissue infiltration and damage (fibrosis/collagen deposition). Nevertheless, this MAS model has allowed us to deepen our understanding of the early events that are upstream of the disease development. Indeed, we showed that in livers of mice with MAS, the number of CD68 1 macrophages and expression of IL-12, mainly produced by M1 macrophages, was increased compared with that in WT mice.
In conclusion, in this study we found a role for high levels of IL-6 in inducing increased macrophage infiltration and upregulation of Il12 expression in the liver and demonstrated the pivotal role of IFN-g in a murine model of MAS. Our data, together with those obtained in animal models of pHLH and of HLH secondary to infections, [17] [18] [19] 28 support the hypothesis that HLH forms of different origin share a common inflammatory effector pathway involving IFN-g. Our results also have significant implications for the treatment of patients with MAS. Encouraging preliminary efficacy and safety data of the phase 2 clinical trial in patients with pHLH with the anti-IFN-g mAb NI-0501 have been reported recently. 41 
Key messages
d In a murine model of MAS, the IFN-g pathway is markedly activated in the liver and spleen in the early phase of the disease.
d IFN-g neutralization ameliorates survival and clinical and laboratory features of MAS.
d Tissue and circulating levels of the IFN-g-inducible chemokines CXCL9 and CXCL10 reflect activation of the pathway and might represent biomarkers of disease in human patients with MAS.
